Although the overall mutation frequency of KRAS in cutaneous melanoma may be less pronounced than that of BRAF or NRAS, the current findings reinforce the concept that KRAS pathway activation is sufficiently relevant to warrant deeper examination (14). This evidence concerns the gene NRAS and cutaneous melanoma.